Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haematologica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature.
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse Generally, the optimal therapeutic approach for the treatment of MRD should be associated with a reliable efficacy and also well tolerated. The DNA-methylation inhibitor 5-azacitidine (AZA) seems to be a promising drug for this treatment indication. Indeed, it is active in patients with AML and advanced myelodysplastic syndrome (MDS) 6 , has a low rate of extramedullary toxicity and can be administered on an outpatient basis.
We report for the first time a considerable number of patients (n=10) with NK-AML and NPM1 mutation (NPM1+) who underwent preemptive treatment with AZA to avoid HR (Table 1 ). All patients were in 1 st or 2 nd complete remission (CR) after intensive pretreatment with conventional chemotherapy, autologous or allogeneic HSC but displayed molecularly detectable MRD consistent with imminent relapse. One of these patients has already been published as a case report in 2010, however only with a short follow up, which has been extended now 7 .. According to our institutional guidelines MRD screening was routinely performed during the disease course by using sequential real-time PCR specific for NPM1 mutants A, B, and D in bone marrow and peripheral blood samples as described in recent studies 4, 7 . In cases of molecular relapse or persistent MRD defined as an increase or a persistence of NPM1/ABL ratio >1% in the bone marrow after the last therapy, preemptive treatment with AZA was initiated at a dose of 75 mg/m 2 /day s.c. on days 1-7 every 28 days. Two patients received dose-modified therapy (100 mg/day, days 1-5). Molecular response was defined as a minimum of 1-log MRD reduction compared to the baseline MRD value before treatment initiation.
Patients started treatment of MRD with AZA at a median NPM1/ABL ratio of 194% (range 3%-7129%) in the bone marrow. The median time from last therapy to molecular relapse was 7 months. At this time point all patients were still in CR with a median neutrophil and platelet count of 3.1 Gpt/l and 137 Gpt/l, respectively. A median of 5 cycles were given (range, 2-12 cycles) and usually well tolerated. The most frequent side effect was myelosuppression with reversible neutropenia and thrombocytopenia grades 3/4 in 80% and 40% of patients, respectively. Although similar results were reported in the AZA001 study 6 , these patients had a manifest active disease, whereas in our study they were treated for MRD, being otherwise not impaired by the imminent disease recurrence. Therefore, patients
undergoing AZA treatment for MRD should be monitored closely to avoid reduction in their quality of life due to cytopenia associated complications. Nevertheless, in future trials the dose of AZA might be further reduced possibly without loosing its efficiency as recently described by Lima et al 8 .
After a median follow up time of 10 months (range, 2-12 months) from initiation of AZA treatment only 3 patients developed a hematologic relapse. A molecular response with an at least 1-log decrease in the MRD level was observed in seven of the 10 (70%) patients. Five of them responded within 3 cycles, another 2 patients responded after cycle 4 and 5.
However, some patients had only a temporary response consistent with the statement that AZA treatment might only have delayed the time to hematologic relapse in some patients. A stable course of MRD was documented in 1 patient and early progressive increase of the NPM1+ clone despite AZA treatment was observed in 2 patients.
Interestingly, the 2 patients with the highest NPM1+ values (>1000%) before initiation of AZA treatment ultimately relapsed after 4 and 6 cycles, respectively. This might reflect the existence of a threshold above which a patient is not likely to benefit for a long time from preemptive AZA application.
Among the seven responders there were three patients suffering from molecular relapse after precedent allogeneic SCT. One of these showed complete clearance of NPM1+ after 4 cycles. We therefore speculate that AZA, besides its direct effects on leukemic cells, might also influence the donor immune system and reconstitute the graft versus leukemia (GvL) effect as suggested recently 9 .
Taken together, the results of the present analysis are promising, especially when considering the published data describing the natural disease course in NPM1+ AML, with disease progression to full clinical relapse within a median of 8 weeks after detection of MRD 4, 5, 10 . In contrast to these data, we found 7 of 10 patients being still in complete hematologic remission after a median follow-up time of 10 months, suggesting a potential efficacy of AZA in NPM1-defined treatment of MRD. Especially elderly patients and those with a history of serious treatment-related toxicities may benefit from this well tolerable treatment approach.
Furthermore, for patients with no available matched donor at the time of molecular relapse, this strategy might be preferable for bridging to subsequent allogeneic HSCT.
Further investigations are necessary to define the patient population who will have the most benefit from this treatment approach. Since our study included only a relatively small number of patients, prospective clinical trials addressing the impact of MRD-directed therapy with AZA in NPM1 mutant AML are warranted. 
